JP2019532267A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532267A5
JP2019532267A5 JP2019508809A JP2019508809A JP2019532267A5 JP 2019532267 A5 JP2019532267 A5 JP 2019532267A5 JP 2019508809 A JP2019508809 A JP 2019508809A JP 2019508809 A JP2019508809 A JP 2019508809A JP 2019532267 A5 JP2019532267 A5 JP 2019532267A5
Authority
JP
Japan
Prior art keywords
protein
sample
salt
nanoparticles
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019508809A
Other languages
English (en)
Japanese (ja)
Other versions
JP6959327B2 (ja
JP2019532267A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/047630 external-priority patent/WO2018035470A1/en
Publication of JP2019532267A publication Critical patent/JP2019532267A/ja
Publication of JP2019532267A5 publication Critical patent/JP2019532267A5/ja
Priority to JP2021165510A priority Critical patent/JP7321227B2/ja
Application granted granted Critical
Publication of JP6959327B2 publication Critical patent/JP6959327B2/ja
Priority to JP2023120438A priority patent/JP2023139189A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019508809A 2016-08-18 2017-08-18 濃度依存性自己相互作用ナノ粒子分光法を用いて、タンパク質が自己会合する可能性を決定するアッセイ Active JP6959327B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021165510A JP7321227B2 (ja) 2016-08-18 2021-10-07 濃度依存性自己相互作用ナノ粒子分光法を用いて、タンパク質が自己会合する可能性を決定するアッセイ
JP2023120438A JP2023139189A (ja) 2016-08-18 2023-07-25 濃度依存性自己相互作用ナノ粒子分光法を用いて、タンパク質が自己会合する可能性を決定するアッセイ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376788P 2016-08-18 2016-08-18
US62/376,788 2016-08-18
PCT/US2017/047630 WO2018035470A1 (en) 2016-08-18 2017-08-18 Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021165510A Division JP7321227B2 (ja) 2016-08-18 2021-10-07 濃度依存性自己相互作用ナノ粒子分光法を用いて、タンパク質が自己会合する可能性を決定するアッセイ

Publications (3)

Publication Number Publication Date
JP2019532267A JP2019532267A (ja) 2019-11-07
JP2019532267A5 true JP2019532267A5 (enExample) 2020-07-16
JP6959327B2 JP6959327B2 (ja) 2021-11-02

Family

ID=59746357

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019508809A Active JP6959327B2 (ja) 2016-08-18 2017-08-18 濃度依存性自己相互作用ナノ粒子分光法を用いて、タンパク質が自己会合する可能性を決定するアッセイ
JP2021165510A Active JP7321227B2 (ja) 2016-08-18 2021-10-07 濃度依存性自己相互作用ナノ粒子分光法を用いて、タンパク質が自己会合する可能性を決定するアッセイ
JP2023120438A Pending JP2023139189A (ja) 2016-08-18 2023-07-25 濃度依存性自己相互作用ナノ粒子分光法を用いて、タンパク質が自己会合する可能性を決定するアッセイ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021165510A Active JP7321227B2 (ja) 2016-08-18 2021-10-07 濃度依存性自己相互作用ナノ粒子分光法を用いて、タンパク質が自己会合する可能性を決定するアッセイ
JP2023120438A Pending JP2023139189A (ja) 2016-08-18 2023-07-25 濃度依存性自己相互作用ナノ粒子分光法を用いて、タンパク質が自己会合する可能性を決定するアッセイ

Country Status (19)

Country Link
US (3) US11428695B2 (enExample)
EP (2) EP3500856B1 (enExample)
JP (3) JP6959327B2 (enExample)
KR (3) KR102717462B1 (enExample)
CN (2) CN115468919A (enExample)
AU (2) AU2017313150B2 (enExample)
BR (1) BR112019003175A2 (enExample)
CA (3) CA3254461A1 (enExample)
DK (2) DK3500856T3 (enExample)
EA (1) EA201990316A1 (enExample)
ES (2) ES2974961T3 (enExample)
FI (1) FI3761035T3 (enExample)
HU (2) HUE052805T2 (enExample)
IL (2) IL264640B2 (enExample)
MX (2) MX2019001930A (enExample)
PL (2) PL3500856T3 (enExample)
SG (1) SG11201900895QA (enExample)
WO (1) WO2018035470A1 (enExample)
ZA (1) ZA201901035B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052805T2 (hu) 2016-08-18 2021-05-28 Regeneron Pharma Fehérje önasszociációs képességének meghatározására szolgáló assay koncentrációfüggõ öninterakciós nanorészecske-spektroszkópia segítségével
PT4364724T (pt) 2018-05-10 2025-12-16 Regeneron Pharma Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada
CN113588582B (zh) * 2020-04-30 2024-05-14 上海药明生物技术有限公司 蛋白质样品浓度测定方式选择法及测定方法
WO2023095154A1 (en) * 2021-11-24 2023-06-01 Sensoville Biotech Pvt Ltd Method for determining changes in a protein's structure
WO2023141319A1 (en) * 2022-01-24 2023-07-27 Amgen Inc. Methods for detecting antibody self-association
CN119832975A (zh) * 2024-12-24 2025-04-15 上海药明生物技术有限公司 一种蛋白质共处方制剂的稳定性预测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US771997A (en) 1903-11-21 1904-10-11 Alfred Palm Lathe attachment.
US4254102A (en) * 1975-09-08 1981-03-03 Plough, Inc. Substantive PABA compositions
US4080264A (en) 1976-03-01 1978-03-21 Massachusetts Institute Of Technology Immunoassay by light scattering spectroscopy
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20050214356A1 (en) * 2004-03-24 2005-09-29 Joyce Timothy H Self assembling activation agents targeted using active drug release
US20050221507A1 (en) * 2004-03-30 2005-10-06 Intel Corporation Method to detect molecular binding by surface-enhanced Raman spectroscopy
US7514938B2 (en) 2004-05-11 2009-04-07 Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno Dielectric relaxation spectroscopy apparatus and methods of use
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
ES2352509T3 (es) * 2005-05-02 2011-02-21 Baseclick Gmbh Nuevas estrategias de marcaje para la detección sensible de analitos.
US20070291265A1 (en) 2006-04-13 2007-12-20 Mississippi State University Optical apparatus for simultaneously measuring the scattering and concentration of signals of macromolecules in a flow cell
JP2010506839A (ja) 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
GB0621050D0 (en) * 2006-10-23 2006-11-29 Univ Strathclyde Functionalised polymers for labelling metal surfaces
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2009039502A1 (en) * 2007-09-21 2009-03-26 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
US20110305765A1 (en) 2008-11-21 2011-12-15 Board Of Regents, The University Of Texas System Preparation and methodology of silk fibroin nanoparticles
US20140024024A1 (en) * 2012-07-17 2014-01-23 General Electric Company Methods of detecting dna, rna and protein in biological samples
JP6099108B2 (ja) 2013-05-30 2017-03-29 公立大学法人大阪府立大学 被検出物質の検出装置および方法
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP2902503A1 (en) * 2014-01-31 2015-08-05 Fundación Imdea Nanociencia Functionalized metal nanoparticles and uses thereof for detecting nucleic acids
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
CN104062287B (zh) 2014-07-01 2017-08-08 福建工程学院 一种基于纳米金催化的化学发光分析检测铁蛋白的方法
MA40861A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2016115475A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Anti-cd40 antibody formulations
HUE052805T2 (hu) 2016-08-18 2021-05-28 Regeneron Pharma Fehérje önasszociációs képességének meghatározására szolgáló assay koncentrációfüggõ öninterakciós nanorészecske-spektroszkópia segítségével

Similar Documents

Publication Publication Date Title
JP2019532267A5 (enExample)
CN112057419B (zh) 单克隆抗体的配制品
JP7473603B2 (ja) 液体医薬組成物
JP2023139189A5 (enExample)
ES2313881T3 (es) Formulaciones de vacunas frente al papilomavirus humano.
ES2659981T3 (es) Formulación farmacéutica que comprende un fármaco biofarmacéutico
CN109475597B (zh) 眼用药物组合物
EA028945B1 (ru) СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα)
CN102711833A (zh) 蛋白质药物制剂
JP2019504086A5 (enExample)
JPWO2012111762A1 (ja) 抗ｃｄ４０抗体の高濃度製剤
JP2021521231A (ja) 熱安定性を改善するためのタンパク質製剤のための添加剤
FI3761035T3 (fi) Analyysi proteiinin itseassosiaatiomahdollisuuden määrittämiseksi käyttäen pitoisuudesta riippuvaa itseinteraktio-nanopartikkelispektroskopiaa
WO2016120413A1 (en) Pharmaceutical formulations for anti-tnf-alpha antibodies
JP2019070016A (ja) ヘプラペプチドの製剤
JP6813355B2 (ja) 新規な安定製剤
EP3911298B1 (en) Formulations
IL315632A (en) Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
CN112312890A (zh) 稳定的杂合fc融合g-csf制剂
BR112014001921B1 (pt) Formulação aquosa farmaceuticamente aceitável, método para aumentar a estabilidade de uma formulação aquosa farmaceuticamente aceitável e embalagem principal
Hamrin Aggregation mechanisms of proteins in liquid formulations
Hammad The Stability of Adenoviral and mRNA Based COVID-19 Vaccines and the Potential of HSA
WO2024118542A1 (en) A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions
HK40064304A (en) Formulations
Abu Hammad Part A: The stability of Adenoviral and mRNA based COVID-19 vaccines and the potential of HSA/Part B: Characterisation of IgG A33 hFab’and human serum albumin using hydrodynamic methods